Fierce Pharma July 12, 2024
Even as pharma companies have yet to feel the full effects of the Inflation Reduction Act, Senate lawmakers have turned their attention to another facet of drug pricing with a bill meant to crack down on the industry’s aggressive patenting practices.
Thursday, the Senate unanimously the bipartisan Affordable Prescriptions for Patients Act, which looks to limit the number of patents drugmakers can assert in litigation on individual biological products. The bill aims to fight “patent thicketing,” a tactic the branded drug industry uses to delay or thwart competition.
Patent thicketing occurs when drug companies stack secondary drug patents to create a complex web of intellectual property that’s hard for generic or biosimilars developers to navigate. AbbVie, for example, was able...
Today's Sponsors
Today's Sponsor